RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION
- 1 April 1985
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 325 (8433), 842-847
- https://doi.org/10.1016/s0140-6736(85)92208-1
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.Circulation, 1984
- Coronary Thrombolysis for Evolving Myocardial InfarctionDrugs, 1984
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator.Cell Metabolism, 1984
- Thrombolytic TherapyNew England Journal of Medicine, 1984
- Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase.Cell Metabolism, 1984
- Coronary Thrombolysis with Tissue-Type Plasminogen Activator in Patients with Evolving Myocardial InfarctionNew England Journal of Medicine, 1984
- Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.Circulation, 1984
- Cardiovascular reflexes stimulated by reperfusion of ischemic myocardium in acute myocardial infarction.Cell Metabolism, 1983
- Reperfusion arrhythmia: A marker of restoration of antegrade flow during intracoronary thrombolysis for acute myocardial infarctionAmerican Heart Journal, 1983
- A Table of Exact Confidence Limits for Differences and Ratios of Two Proportions and Their Odds RatiosJournal of the American Statistical Association, 1977